Biogen halts studies of closely watched Alzheimer’s drug, a blow to hopes for new treatment
Biogen halts study of closely watched Alzheimer’s drug, a blow to hopes for new treatment.
Alzheimer’s disease has beaten back another effort to tame it.
Biogen and its Japanese pharma partner Eisai said Thursday that they were halting two Phase 3 clinical trials of aducanumab, a drug that was designed to slow the worsening of Alzheimer’s by known as beta-amyloid.
